Correction: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women [Breast Cancer Res., 12, 4, (2010) (R57)] DOI: 10.1186/bcr2618;Association of invasion-promoting tenascin-C additional domains with breast cancers in young women

Breast Cancer Research

Volumn 12, Issue 4, 2010, Pages

  Guttery, David S ^a   Hancox, Rachael A ^a   Mulligan, Kellie T ^b   Hughes, Simon ^b   Lambe, Sinead M ^a   Pringle, J Howard ^a   Walker, Rosemary A ^a   Jones, J Louise ^b   Shaw, Jacqueline A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; TENASCIN; ISOPROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; DISEASE ASSOCIATION; FEMALE; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PROTEIN DOMAIN; PROTEIN EXPRESSION; RNA ANALYSIS; TISSUE DISTRIBUTION; AGE; BINDING SITE; BREAST; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; EPITHELIUM; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGE FACTORS; BINDING SITES; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIUM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEOPLASM INVASIVENESS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TENASCIN;

EID: 78650901947     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-018-0997-8     Document Type: Erratum

References (60)

1. Radisky DC, Bissell MJ. Cancer. Respect thy neighbor!. Science 2004, 303:775-777. 10.1126/science.1094412, 14764858.
2. Roskelley CD, Bissell MJ. The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol 2002, 12:97-104. 10.1006/scbi.2001.0417, 12027581.
3. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002, 38:2362-2370. 10.1016/S0959-8049(02)00210-1, 12460779.
4. Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, Haglund C, Nevanlinna H, Blomqvist C. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer 1998, 78:1507-1513. 2063217, 9836485.
5. Jones PL. Extracellular matrix and tenascin-C in pathogenesis of breast cancer. Lancet 2001, 357:1992-1994. 10.1016/S0140-6736(00)05133-3, 11438127.
6. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996, 7:883-892. 275940, 8816995.
7. Ghert MA, Qi WN, Erickson HP, Block JA, Scully SP. Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. Cell Struct Funct 2001, 26:179-187. 10.1247/csf.26.179, 11565810.
8. Phillips GR, Krushel LA, Crossin KL. Domains of tenascin involved in glioma migration. J Cell Sci 1998, 111:1095-1104.
9. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 1991, 115:1127-1136. 10.1083/jcb.115.4.1127, 2289958, 1720121.
10. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 2000, 105:21-34. 10.1172/JCI6539, 382582, 10619858.
11. Schenk S, Chiquet-Ehrismann R, Battegay EJ. The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. Mol Biol Cell 1999, 10:2933-2943. 25533, 10473637.
12. Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell 1994, 5:439-453. 301053, 7519905.
13. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146. 10.1016/S0092-8674(00)81009-0, 2853255, 10428026.
14. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000, 19:581-596. 10.1016/S0945-053X(00)00106-2, 11102748.
15. Prieto AL, Edelman GM, Crossin KL. Multiple integrins mediate cell attachment to cytotactin/tenascin. Proc Natl Acad Sci USA 1993, 90:10154-10158. 10.1073/pnas.90.21.10154, 47732, 7694284.
16. Weber P, Ferber P, Fischer R, Winterhalter KH, Vaughan L. Binding of contactin/F11 to the fibronectin type III domains 5 and 6 of tenascin is inhibited by heparin. FEBS Lett 1996, 389:304-308. 10.1016/0014-5793(96)00609-6, 8766721.
17. Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol 1994, 126:539-548. 10.1083/jcb.126.2.539, 2200039, 7518469.
18. Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995, 270:8650-8654. 10.1074/jbc.270.15.8650, 7536739.
19. Ljubimov AV, Saghizadeh M, Spirin KS, Khin HL, Lewin SL, Zardi L, Bourdon MA, Kenney MC. Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci 1998, 39:1135-1142.
20. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1992, 52:688-692. 10.1002/ijc.2910520504, 1385335.
21. Dueck M, Riedl S, Hinz U, Tandara A, Moller P, Herfarth C, Faissner A. Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int J Cancer 1999, 82:477-483. 10.1002/(SICI)1097-0215(19990812)82:4<477::AID-IJC2>3.0.CO;2-5, 10404058.
22. Hindermann W, Berndt A, Borsi L, Luo X, Hyckel P, Katenkamp D, Kosmehl H. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999, 189:475-480. 10.1002/(SICI)1096-9896(199912)189:4<475::AID-PATH462>3.0.CO;2-V, 10629546.
23. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 1999, 154:1345-1352. 1866608, 10329587.
24. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002, 62:3289-3297.
25. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009, 11:R24. 10.1186/bcr2251, 2688953, 19405959.
26. Wilson KE, Langdon SP, Lessells AM, Miller WR. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br J Cancer 1996, 74:999-1004. 2077103, 8855965.
27. Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 2003, 162:1857-1867. 1868127, 12759243.
28. Mighell AJ, Thompson J, Hume WJ, Markham AF, Robinson PA. Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae. Int J Cancer 1997, 72:236-240. 10.1002/(SICI)1097-0215(19970717)72:2<236::AID-IJC6>3.0.CO;2-S, 9219826.
29. Sriramarao P, Bourdon MA. A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices. Nucleic Acids Res 1993, 21:163-168. 10.1093/nar/21.1.163, 309079, 7680113.
30. Tucker RP, Spring J, Baumgartner S, Martin D, Hagios C, Poss PM, Chiquet-Ehrismann R. Novel tenascin variants with a distinctive pattern of expression in the avian embryo. Development 1994, 120:637-647.
31. Derr LB, Chiquet-Ehrismann R, Gandour-Edwards R, Spence J, Tucker RP. The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species. Differentiation 1997, 62:71-82. 10.1046/j.1432-0436.1997.6220071.x, 9404002.
32. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006, 12:3200-3208. 10.1158/1078-0432.CCR-05-2804, 16707621.
33. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
34. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
35. Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol 2003, 201:562-572. 10.1002/path.1483, 14648659.
36. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180. 10.1158/1078-0432.CCR-04-2424, 16033833.
37. Partridge J, Flaherty P. An in vitro FluoroBlok tumor invasion assay. J Vis Exp 2009, pii: 1475.
38. Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G, Mellon JK, Tulchinsky E. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell 2007, 18:4615-4624. 10.1091/mbc.E07-05-0406, 2043563, 17855508.
39. Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS. Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res 2007, 9:404. 10.1186/bcr1827, 2246182, 18279542.
40. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007, 50:434-438. 10.1111/j.1365-2559.2007.02638.x, 17448018.
41. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005, 11:4003-4011. 10.1158/1078-0432.CCR-04-2064, 15930334.
42. NCBI Blast. , http://blast.ncbi.nlm.nih.gov/Blast.cgi
43. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
44. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 1992, 52:5190-5197.
45. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992, 150:534-544. 10.1002/jcp.1041500314, 1537883.
46. Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer 2003, 106:8-16. 10.1002/ijc.11172, 12794751.
47. Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, Oakeley EJ, Chiquet-Ehrismann R, Orend G. Growth promoting signaling by tenascin-C [corrected]. Cancer Res 2004, 64:7377-7385. 10.1158/0008-5472.CAN-04-1234, 15492259.
48. Lange K, Kammerer M, Saupe F, Hegi ME, Grotegut S, Fluri E, Orend G. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res 2008, 68:6942-6952. 10.1158/0008-5472.CAN-08-0347, 18757408.
49. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009, 3:287-310. 10.1007/s12079-009-0075-1, 2778592,2778592, 19838819.
50. Cai M, Onoda K, Takao M, Kyoko IY, Shimpo H, Yoshida T, Yada I. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res 2002, 8:1152-1156.
51. Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 1994, 352:216-218. 10.1016/0014-5793(94)00960-0, 7523186.
52. Saito Y, Imazeki H, Miura S, Yoshimura T, Okutsu H, Harada Y, Ohwaki T, Nagao O, Kamiya S, Hayashi R, Kodama H, Handa H, Yoshida T, Fukai F. A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J Biol Chem 2007, 282:34929-34937. 10.1074/jbc.M705608200, 17901052.
53. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 2008, 14:5555-5564. 10.1158/1078-0432.CCR-08-0555, 18765548.
54. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986, 315:559-563. 10.1056/NEJM198608283150906, 3736639.
55. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996, 77:97-103. 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3, 8630946.
56. Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996, 74:1796-1800. 2077218, 8956795.
57. Pillers EM. Histological grade of breast cancer in younger women. Lancet 1992, 339:1483. 10.1016/0140-6736(92)92079-U, 1351156.
58. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993, 341:1039-1043. 10.1016/0140-6736(93)92407-K, 8096955.
59. Johnson SM, Shaw JA, Walker RA. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer 2002, 98:205-209. 10.1002/ijc.10197, 11857409.
60. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376. 10.1158/1078-0432.CCR-07-1658, 18316557.